stockrowInspireMD, Inc.
NSPR Healthcare Medical Devices
InspireMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, up 28.1% from fiscal 2024.
- Revenue
- −0.39%
- EPS
- +34.6%
- Free cash flow
- −26.0%
Quarter to June 2026, against a year earlier
Follow NSPR
Alert me
InspireMD, Inc. (NSPR) EV/Sales
As of 5 November 2026, InspireMD, Inc. (NSPR) trades at a EV/Sales of 2.5×. Over the past ten years it has ranged from −5.4× (May 2021) to 7,252,565× (January 2015); the current reading is higher than 65% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.1× | (37.02%) |
| FY2024 | 11.3× | 130.33% |
| FY2023 | 4.9× | — |
| FY2022 | −1.3× | — |
| FY2021 | −1.8× | — |
| FY2020 | −0.5× | — |
| FY2019 | 0.1× | — |
| FY2018 | −0.5× | — |
| FY2017 | 0.6× | (50.45%) |
| FY2016 | 1.3× | 50.57% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.0× | (66.96%) |
| Mar 2026 | 9.1× | 27.65% |
| Dec 2025 | 7.1× | (52.73%) |
| Sep 2025 | 15.1× | 6.47% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NSYS Nortech Systems Incorporated compare | 0.2× |
| XTNT Xtant Medical Holdings, Inc. compare | 0.5× |
| CVRX CVRx, Inc. compare | 0.7× |
| RPID Rapid Micro Biosystems, Inc. compare | 0.8× |
| TELA TELA Bio, Inc. compare | 1.0× |
| QTI QT Imaging Holdings, Inc. compare | 1.3× |
| NSPR InspireMD, Inc. | 2.5× |
| MDAI Spectral AI, Inc. compare | 2.7× |
| ELUT Elutia Inc. compare | 3.4× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)